Pharming Group Announces Positive Phase II Topline Data For Leniolisib In Pids With Immune Dysregulation

By Reuters News

- Pharming Group N.V. PHAR.AS:

  • ANNOUNCES POSITIVE PHASE II TOPLINE DATA FOR LENIOLISIB IN PIDS WITH IMMUNE DYSREGULATION ACCEPTED AS LATE-BREAKING ABSTRACT AT ESID 2026

  • EXPECTS TO REPORT TOPLINE RESULTS FROM A PHASE II TRIAL OF LENIOLISIB IN CVID IN Q4 2026

Further company coverage: PHAR.AS

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk